Investment
Features
FeesSafety
Academy
More
Pluang+

Compare GraniteShares 2x Long COIN Daily ETF (CONL) vs Crispr Therapeutics AG (CRSP) Price & Performance

GraniteShares 2x Long COIN Daily ETFTrade
Crispr Therapeutics AGTrade

Price performance (Past 24H)

Key statistics

GraniteShares 2x Long COIN Daily ETF vs Crispr Therapeutics AG — how do they compare? GraniteShares 2x Long COIN Daily ETF trades at $4.06, while Crispr Therapeutics AG trades at $53.81 (market cap $5.23B). The key difference: Crispr Therapeutics AG is trading nearer its 52-week high, GraniteShares 2x Long COIN Daily ETF nearer its low. Which is the better fit depends on your goals.

CONLCRSP
Sector
Leveraged / InverseHealth
52-Week High
$48.70$76.78
52-Week Low
$3.93$44.34
Market Cap
$5.23B
Enterprise Value
$3.65B

Aura AI Summary

Signals from Pluang's Aura AI — not financial advice

GraniteShares 2x Long COIN Daily ETF

CONL (GraniteShares 2x Long COIN Daily ETF) trades at $4.065, down 0.61% on the day, with a bearish technical outlook as moving averages and key indicators signal selling pressure. The ETF has experienced significant volatility, losing 67% year-to-date according to 24/7 Wall Street (2026-06-06), reflecting the inherent risks of daily-reset leveraged strategies. Recent news highlights the challenges of timing leveraged ETF investments, with investors missing substantial returns due to poor trading timing.

The outlook remains challenging given the ETF's structure amplifies daily Coinbase volatility. While cryptocurrency trends may offer occasional upside, the daily reset mechanism creates compounding risks that have eroded value significantly. Investors should understand this is a tactical trading instrument, not a long-term investment vehicle, with high risk of capital erosion during volatile periods.

Crispr Therapeutics AG

CRISPR Therapeutics (CRSP) trades at $53.83, up 0.6% on the day, with a bullish technical signal from moving averages but overbought RSI readings. The company reported a Q2 2026 EPS beat with a loss of $0.94 versus an expected $1.19 loss, driven by surging CASGEVY sales. However, financials show deep losses, with a net income margin of -4,101.26% in 2025 and negative operating cash flow, though financing activities provided liquidity.

The outlook is mixed: strong analyst consensus (57.9% buy ratings) and a $82.67 price target reflect optimism around CASGEVY growth and pipeline catalysts, but high valuation (P/S of 466.05) and persistent cash burn pose significant risks. Investment appeal hinges on successful clinical advancements and path to profitability.

Returns comparison

Trailing returns across standard periods

About GraniteShares 2x Long COIN Daily ETF

CONL is a leveraged ETF that seeks to provide two times (2x) the daily performance of Coinbase Global (COIN) stock. It is designed for investors seeking magnified short-term exposure to the price movements of Coinbase.

Read more on CONL

About Crispr Therapeutics AG

CRISPR Therapeutics is a gene editing company focused on the development of CRISPR/Cas9-based therapeutics. CRISPR/Cas9 stands for Clustered Regularly Interspaced Short Palindromic Repeats (CRISPR)/CRISPR-associated protein 9 (Cas9), which is a revolutionary technology for precisely altering specific sequences of genomic DNA. The company is focused on using this technology to treat genetically defined diseases. CRISPR's most advanced pipeline candidate, CTX001, is in collaboration with Vertex Pharmaceuticals and targets sickle cell disease and transfusion-dependent beta-thalassemia, which have high unmet medical needs. The company is progressing additional gene editing programs for immuno-oncology, as well as a stem cell-derived therapy for the treatment of Type 1 diabetes.

Read more on CRSP